NCT06607848

Brief Summary

Intra-individual comparison of the PureSee EDOF IOL with the Acunex Vario EDOF IOL set for emmetropia.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
1mo left

Started Jul 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress92%
Jul 2024Jul 2026

Study Start

First participant enrolled

July 29, 2024

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 19, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 23, 2024

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2026

Expected
Last Updated

September 23, 2024

Status Verified

September 1, 2024

Enrollment Period

11 months

First QC Date

September 19, 2024

Last Update Submit

September 19, 2024

Conditions

Keywords

EDOF IOLpresbyopia-correctionCataract

Outcome Measures

Primary Outcomes (1)

  • Distance corrected visual acuity for intermediate distance

    Distance corrected visual acuity for intermediate distance given in logMAR will be measured at 66 cm using ETDRS charts

    6 months

Secondary Outcomes (7)

  • Uncorrected visual acuity for intermediate distance

    6 months

  • Uncorrected and distance corrected visual acuity for far distance

    6 months

  • Uncorrected and distance corrected visual acuity for near distance

    6 months

  • Defocus curve assessment

    6 months

  • Halometry

    6 months

  • +2 more secondary outcomes

Study Arms (2)

Acunex Vario AN6V

EXPERIMENTAL

Patients will receive the Acunex IOL during cataract surgery

Device: Low-Add EDOF IOL

PureSee

EXPERIMENTAL

Patients will receive the PureSee IOL during cataract surgery

Device: EDOF IOL

Interventions

Acunex Vario AN6V

Acunex Vario AN6V
EDOF IOLDEVICE

PureSee EDOF IOL

PureSee

Eligibility Criteria

Age21 Years - 105 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age-related bilateral cataract
  • Age 21 or older
  • Visual acuity \> 0.05
  • For patients with regular corneal astigmatism greater than or equal to 1.00 dpt toric IOLs will be implanted
  • Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically relevant
  • Written informed consent prior to surgery

You may not qualify if:

  • Active ocular disease (e.g chronic uveitis, diabetic retinopathy, chronic glaucoma not responsive to medication, corneal dystrophies, etc.) precluding good post-operative visual acuity
  • Relevant other ophthalmic diseases such as pseudoexfoliation syndrome (PEX)
  • Corneal decompensation or corneal endothelial cell insufficiency
  • Irregular astigmatism on corneal tomography
  • Pronounced dry eye disease
  • Previous ocular surgery or trauma
  • Persons who are pregnant or nursing (pregnancy test will be taken in women of reproductive age)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna

Vienna, Austria, 1140, Austria

RECRUITING

MeSH Terms

Conditions

Cataract

Condition Hierarchy (Ancestors)

Lens DiseasesEye Diseases

Study Officials

  • Oliver Findl, Univ. Prof. Prim. Dr.

    Vienna Institute for Research in Ocular Surgery (VIROS)

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Johannes Zeilinger, MD

CONTACT

Manuel Ruiss, MSc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 19, 2024

First Posted

September 23, 2024

Study Start

July 29, 2024

Primary Completion

July 1, 2025

Study Completion (Estimated)

July 1, 2026

Last Updated

September 23, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share

Locations